The European Brain Council’s Virtual Exhibition:
Living with MS during COVID-19: A case for rethinking MS care in the EU
Dear Visitor,
Welcome to the European Brain Council’s first virtual exhibition ‘Living with MS during COVID-19: A case for rethinking MS care in the EU’.
The COVID-19 pandemic affected us all, but it did not affect us all equally. People living with chronic conditions, such as Multiple Sclerosis (MS), have faced uncertainty and disruptions in their care pathways, and as a consequence, have dealt and will continue to deal with long-term physical and emotional implications of not receiving optimal care.
About the virtual exhibition
Through this unique exhibition, you will be able to view portraits of people supporting EBC’s RETHINKING MS call. The portraits feature people living with MS, clinicians, care givers, policymakers and industry representatives who want to make a difference in how MS care and treatment are delivered in Europe. While you navigate the exhibition, you will also come across videos and infographics showcasing the critical need for improved, patient-centred treatment.
To learn more about why we need to rethink the delivery of care and treatment for people living with MS, we invite you to visit our virtual exhibition below.
The virtual exhibition accompanies the launch of EBC’s paper ‘RETHINKING MS in times of COVID-19’. The paper seeks to renew attention and prioritisation of the needs of people living with MS in Europe, and, above all, to call for timely, personalised and adapted care. As we take stock of the lessons learned from the COVID-19 pandemic and vouch to make health a policy priority, there is an unprecedented opportunity to push for rethinking MS care and the way it is delivered.
How to visit the virtual exhibition
You are invited to navigate freely, at your own pace, through the virtual exhibition’s rooms. You can use your mouse, keyboard or even your smartphone to view the exhibitions’ pieces. A useful ‘how to’ info box is also displayed to show you all the ways to navigate this exhibition. If you prefer, you can choose to let the platform automatically guide you through the exhibition rooms.
We hope you enjoy this innovative and immersive experience!
Visit the national extension of the exhibition
National stakeholders across Europe want to make a difference in how MS care and treatment are delivered. They call for the need to rethink MS and MS care in terms of coordination, integration and prioritisation in order to ensure optimal care for people living with MS in Europe. Visit the extended exhibition and hear from the experts on how the MS care was tackled during the COVID-19 pandemic at national level.
About RETHINKING MS in times of COVID-19
The virtual exhibition accompanies the launch of the policy report “RETHINKING MS in times of COVID-19”. This paper is part of the main report “RETHINKING MS in Europe”, a research-driven project offering tangible policy changes to improve the lives of people living with MS across Europe, building on the 2017 Value of Treatment report from the European Brain Council.
The objective of this new chapter is to provide concrete and tangible testimonies from relevant stakeholders – clinicians, MS patients, patient advocates, pharma representatives – impacted by the disruption in care, which proved both an obstacle and an accelerator for the implementation of good practices.
We highlight how the lives of people living with MS and their families have been affected by COVID-19. In addition to providing a voice to those side-lined by the pandemic response, the gathered testimonies shed light on the need to rethink MS and MS care in terms of coordination, integration and prioritisation in order to ensure optimal care for people living with MS in Europe. Our aim is to contribute to continued awareness raising of MS at EU policy level as well as to feed into the current European policy debate on the direct and indirect consequences arising from the COVID-19 pandemic and encourage stakeholder engagement in EU health policy making.
The project “RETHINKING MS in times of COVID-19” is funded by Biogen, Bristol Myers Squibb, Janssen and Novartis.
All outputs are non-promotional and not specific to any particular treatment or therapy.